Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Equillium Inc (EQ)

Equillium Inc (EQ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 202,990
  • Shares Outstanding, K 29,040
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,810 K
  • 60-Month Beta 1.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.47
Trade EQ with:

Options Overview

Details
  • Implied Volatility 112.32%
  • Historical Volatility 75.84%
  • IV Percentile 75%
  • IV Rank 88.26%
  • IV High 115.42% on 04/05/21
  • IV Low 88.96% on 04/09/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 82
  • Open Int (30-Day) 25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.33
  • Number of Estimates 4
  • High Estimate -0.27
  • Low Estimate -0.38
  • Prior Year -0.45
  • Growth Rate Est. (year over year) +26.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.19 +5.98%
on 03/30/21
8.70 -24.60%
on 03/15/21
-1.35 (-17.07%)
since 03/12/21
3-Month
5.10 +28.63%
on 01/14/21
11.33 -42.10%
on 02/12/21
+1.00 (+17.99%)
since 01/13/21
52-Week
2.37 +176.79%
on 04/22/20
27.05 -75.75%
on 07/13/20
+4.02 (+158.27%)
since 04/13/20

Most Recent Stories

More News
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients

Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus

EQ : 6.56 (-0.30%)
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update

Cash runway into the second half of 2023

EQ : 6.56 (-0.30%)
Equillium Announces Positive Data for Itolizumab in Acute Graft-Versus-Host Disease in Two Presentations at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation

EQUATE acute graft-versus host disease (aGVHD) study observed rapid response and durability through day 85

EQ : 6.56 (-0.30%)
Equillium to Present at the H.C. Wainwright Global Life Sciences Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the H.C. Wainwright...

EQ : 6.56 (-0.30%)
Equillium to Present at the SVB Leerink 10th Annual Global Healthcare Conference

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, announced today that it will present at the SVB Leerink...

EQ : 6.56 (-0.30%)
Equillium Presents Positive Interim Clinical Data of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease at the 2021 Transplantation and Cellular Therapy Meetings Digital Experience

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use

EQ : 6.56 (-0.30%)
Equillium Announces the Appointment of Katherine Xu to the Board of Directors

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that Y. Katherine Xu, Ph.D., partner at...

EQ : 6.56 (-0.30%)
Equillium Announces Closing of $30 Million Registered Direct Offering

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced the closing of its previously announced...

EQ : 6.56 (-0.30%)
Equillium Announces Pricing of $30 Million Registered Direct Offering

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that it has entered into a securities purchase...

EQ : 6.56 (-0.30%)
Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience

Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today announced that interim data from the Phase 1b/2 EQUATE...

EQ : 6.56 (-0.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 7.07
2nd Resistance Point 6.87
1st Resistance Point 6.72
Last Price 6.56
1st Support Level 6.37
2nd Support Level 6.17
3rd Support Level 6.02

See More

52-Week High 27.05
Fibonacci 61.8% 17.62
Fibonacci 50% 14.71
Fibonacci 38.2% 11.80
Last Price 6.56
52-Week Low 2.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar